pISSN 1226-6051
eISSN 2508-786X

Table. 2.

Table. 2.

Comorbid Conditions of Osteoporosis Treatments Prescribed Patients, 2018

(unit: person) Anti-resorptives Bone-forming


Bisphosphonates SERMs Denosumab Calcitonin Total Anti-resorptives Teriparatide
Total, n(%) 38,802(86.6%) 6,242(13.9%) 931(2.1%) 1,394(3.1%) 44,697(99.3%) 296(0.7%)
Disease related to secondary osteoporosis, n(%) 5,786(14.9%) 991(15.9%) 203(21.8%) 232(16.6%) 6,720(15.0%) 54(18.2%)
CCI, n(%)
Mean±SD 0.9±1.2 0.9±1.2 1.1±1.4 1.0±1.2 0.9±1.2 1.2±1.3
0 18,539(47.8%) 3,101(49.7%) 437(46.9%) 605(43.4%) 21,452(48.0%) 115(38.9%)
1-2 15,987(41.2%) 2,498(40.0%) 356(38.2%) 616(44.2%) 18,316(41.0%) 129(43.6%)
≥3 4,276(11.0%) 643(10.3%) 138(14.8%) 173(12.4%) 4,929(11.0%) 52(17.6%)
Comorbid conditions, n (%)
Hyperparathyroidism 63(0.16%) 18(0.3%) 11(1.2%) 3(0.2%) 83(0.2%) 0(0.0%)
Skeletal malignancy 58(0.2%) 4(0.1%) 1(0.1%) 1(0.1%) 61(0.1%) 0(0.0%)
Peptic ulcer 6,201(16.0%) 849(13.6%) 157(16.9%) 248(17.8%) 7,002(15.7%) 56(18.9%)
Liver diseases 3,247(8.4%) 485(7.8%) 66(7.1%) 155(11.1%) 3,725(8.3%) 21(7.1%)
Cerebrovascular disease 3,218(8.3%) 434(7.0%) 81(8.7%) 141(10.1%) 3,651(8.2%) 33(11.2%)
Ischaemic heart diseases 3,280(8.0%) 499(9.9%) 92(11.1%) 155(11.2%) 3,774(8.4%) 33(11.2%)
Dementia 3,070(7.9%) 378(6.1%) 84(9.0%) 147(10.6%) 3,454(7.7%) 52(17.6%)

* Comparisons (bone-forming agents vs. anti-resorptives) that are statistically significant at p<0.05 are noted by .

* Patients and prescriptions can be counted in more than one category

* CCI: Charlson comorbidity index

Abbreviation: SD, standard deviation; CCI, Charlson Comorbidity Index; SERMs, Selective Estrogen Receptor Modulators

Korean J Clin Pharm 2021;31:27-34 https://doi.org/10.24304/kjcp.2021.31.1.27
© 2021 Korean J Clin Pharm